skip to Main Content

Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study

Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
Pancreatic ductal adenocarcinoma (PDAC) remains resistant to chemotherapy and immunotherapy individually because of its desmoplastic stroma and immunosuppressive tumor microenvironment. Synergizing cytotoxic T‐lymphocyte–associated antigen 4 (CTLA‐4) immune checkpoint blockade with chemotherapy could overcome these barriers.

Here we present results of a phase Ib trial combining ipilimumab and gemcitabine in advanced PDAC. Read more . . . 


Back To Top